Table 1.
Patient characteristics
| RA [n = 432] | axSpA [n = 240] | Total [N = 672] | |
|---|---|---|---|
| Age (years) | 58.3 (13.1) | 47.0 (13.2) | 54.2 (14.2) |
| Gender (women, %) | 276 (74.0%) | 94 (45.2%) | 370 (63.7%) |
| Professional activity | |||
| In employment | 162 (38.2%) | 167 (70.5%) | 329 (49.8%) |
| Retired | 201 (47.4%) | 30 (12.7%) | 231 (34.9%) |
| Other | 61 (14.4%) | 40 (16.8%) | 101 (15.3%) |
| Education level | |||
| Primary | 77 (18.0%) | 11 (4.6%) | 88 (13.3%) |
| Secondary | 219 (51.3%) | 134 (56.3%) | 353 (53.1%) |
| Tertiary (post-high school) | 131 (30.7%) | 93 (39.1%) | 224 (33.7%) |
| Disease duration (years) | 13.1 (11.4) | 13.8 (10.6) | 13.4 (11.1) |
| Disease activity | |||
| DAS28(ESR) | 2.6 (1.2) | – | – |
| BASDAI | – | 3.3 (2.2) | – |
| Physician global assessment (0–10) | 2.75 (2.12) | 3.44 (2.41) | 3.00 (2.25) |
| Patient global assessment (0–10) | 3.03 (2.45) | 4.27 (2.61) | 3.48 (2.58) |
| Treatments | |||
| Corticosteroids alone | 6 (1.8%) | – | 6 (1.1%) |
| NSAIDs alone | – | 36 (15.1%) | 36 (6.4%) |
| Synthetic DMARDs ± corticosteroids/NSAIDs | 61 (18.7%) | 15 (6.3%) | 76 (13.5%) |
| Biological DMARDs (alone or in combination) | 252 (77.3%) | 173 (72.7%) | 425 (75.4%) |
| Other | 2 (0.6%) | 7 (2.9%) | 9 (0.7%) |
Data are presented as mean values (standard deviation) for continuous variables, and as frequency counts (%) for categorical variables. Data were missing for some patients for all variables
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS28(ESR), 28-item disease activity score measured with erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis